UY27355A1 - Compuestos de espiropiperidina como ligandos para el receptor orl-1 - Google Patents
Compuestos de espiropiperidina como ligandos para el receptor orl-1Info
- Publication number
- UY27355A1 UY27355A1 UY27355A UY27355A UY27355A1 UY 27355 A1 UY27355 A1 UY 27355A1 UY 27355 A UY27355 A UY 27355A UY 27355 A UY27355 A UY 27355A UY 27355 A1 UY27355 A1 UY 27355A1
- Authority
- UY
- Uruguay
- Prior art keywords
- orl
- spyropiperidine
- ligandos
- receiver
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula: o una sal, pro fármaco o solvato del mismo, en la que todos los grupos R1 Y R2 son hidrógeno; A es un azaheteroanillo benzocondensado; W1- W2 es CH2- CH2; X1- X2 es CH2- CH2; y Z es metileno o carbonilo; o similar, es un ligando para el receptor ORL - 1 y es útil para tratar o prevenir el dolor, un trastorno del SNC o similares en mamíferos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30107901P | 2001-06-26 | 2001-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27355A1 true UY27355A1 (es) | 2003-02-28 |
Family
ID=23161844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27355A UY27355A1 (es) | 2001-06-26 | 2002-06-25 | Compuestos de espiropiperidina como ligandos para el receptor orl-1 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20030078278A1 (es) |
EP (1) | EP1399432A1 (es) |
JP (1) | JP2005521630A (es) |
AP (1) | AP2002002562A0 (es) |
BR (1) | BR0211305A (es) |
CA (1) | CA2450550A1 (es) |
MX (1) | MXPA03011956A (es) |
PA (1) | PA8549101A1 (es) |
PE (1) | PE20030132A1 (es) |
SV (1) | SV2003001115A (es) |
UY (1) | UY27355A1 (es) |
WO (1) | WO2003000677A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2466915A1 (en) | 2002-01-28 | 2003-08-07 | Pfizer Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
EP1491212B1 (en) * | 2002-03-29 | 2012-08-08 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
PL377047A1 (pl) * | 2002-09-09 | 2006-01-23 | Janssen Pharmaceutica, N.V. | Hydroksyalkilopodstawione pochodne 1,3,8-triazaspiro [4,5]-dekan-4-onu przydatne w leczeniu zaburzeń, w których pośredniczy receptor ORL-1 |
CA2503720A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
CN101108825A (zh) | 2003-04-04 | 2008-01-23 | 麦克公司 | 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物 |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
US7354925B2 (en) * | 2004-03-29 | 2008-04-08 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists |
WO2005117862A1 (en) * | 2004-06-03 | 2005-12-15 | Pfizer Limited, | Treatment of urinary conditions including incontinence |
MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
EP1890696A4 (en) * | 2005-06-02 | 2010-05-05 | Janssen Pharmaceutica Nv | Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives |
MX2007016217A (es) * | 2005-06-17 | 2008-03-07 | Pfizer | Compuestos de alfa-(aril- o heteroaril-metil)-beta-piperidinopropa namida como antagonista del receptor orl1. |
AU2006257273A1 (en) * | 2005-06-17 | 2006-12-21 | Pfizer Inc. | Alpha-(ARyl-Or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists |
AU2006304305B2 (en) | 2005-10-18 | 2010-04-01 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
JP2009515833A (ja) * | 2005-10-24 | 2009-04-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 3−ピペリジン−4−イル−インドールorl−1受容体モジュレーター |
WO2007057775A1 (en) * | 2005-11-21 | 2007-05-24 | Pfizer Limited | Spiropiperidine derivatives |
GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
BRPI0719210A2 (pt) | 2006-10-12 | 2015-05-05 | Xenon Pharmaceuticals Inc | Uso de compostos espiro-oxindol como agentes terapêuticos |
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
CN103202840B (zh) * | 2006-11-28 | 2015-02-11 | 詹森药业有限公司 | 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐 |
CN101679430B (zh) * | 2007-04-09 | 2013-12-25 | 詹森药业有限公司 | 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物 |
TWI378096B (en) | 2008-06-19 | 2012-12-01 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
EP2488531B1 (en) | 2009-10-14 | 2014-03-26 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
EP3266444A1 (en) | 2010-02-26 | 2018-01-10 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
WO2014146111A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
CN112940075B (zh) * | 2021-01-07 | 2023-03-31 | 渤海大学 | 一种乙酰胆碱酯酶抑制肽及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654287A (en) * | 1970-08-26 | 1972-04-04 | Mead Johnson & Co | Spiroindanylpiperidines |
US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
GB1435054A (en) * | 1974-02-04 | 1976-05-12 | Ici Ltd | Dihydroanthracene derivatives |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
WO1995028389A1 (fr) * | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
ATE276242T1 (de) * | 1997-05-30 | 2004-10-15 | Banyu Pharma Co Ltd | 2-oxoimidazol-derivate |
US6166209A (en) * | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
AU2001288110A1 (en) * | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
-
2002
- 2002-03-06 US US10/092,040 patent/US20030078278A1/en not_active Abandoned
- 2002-05-22 US US10/153,310 patent/US20030078279A1/en not_active Abandoned
- 2002-06-17 US US10/481,210 patent/US20050038060A1/en not_active Abandoned
- 2002-06-17 CA CA002450550A patent/CA2450550A1/en not_active Abandoned
- 2002-06-17 JP JP2003507081A patent/JP2005521630A/ja active Pending
- 2002-06-17 MX MXPA03011956A patent/MXPA03011956A/es unknown
- 2002-06-17 WO PCT/IB2002/002272 patent/WO2003000677A1/en not_active Application Discontinuation
- 2002-06-17 BR BR0211305-8A patent/BR0211305A/pt not_active IP Right Cessation
- 2002-06-17 EP EP02730637A patent/EP1399432A1/en not_active Withdrawn
- 2002-06-20 AP APAP/P/2002/002562A patent/AP2002002562A0/en unknown
- 2002-06-24 PE PE2002000550A patent/PE20030132A1/es not_active Application Discontinuation
- 2002-06-25 UY UY27355A patent/UY27355A1/es not_active Application Discontinuation
- 2002-06-25 SV SV2002001115A patent/SV2003001115A/es unknown
- 2002-06-26 PA PA20028549101A patent/PA8549101A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0211305A (pt) | 2004-07-13 |
US20030078279A1 (en) | 2003-04-24 |
JP2005521630A (ja) | 2005-07-21 |
PE20030132A1 (es) | 2003-02-28 |
PA8549101A1 (es) | 2003-01-24 |
US20030078278A1 (en) | 2003-04-24 |
CA2450550A1 (en) | 2003-01-03 |
SV2003001115A (es) | 2003-03-18 |
US20050038060A1 (en) | 2005-02-17 |
WO2003000677A1 (en) | 2003-01-03 |
AP2002002562A0 (en) | 2002-06-30 |
EP1399432A1 (en) | 2004-03-24 |
MXPA03011956A (es) | 2004-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27355A1 (es) | Compuestos de espiropiperidina como ligandos para el receptor orl-1 | |
IL155702A0 (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
DE602004030051D1 (de) | Nicht-sedierender A-2 Agonist 1-(2,3-Dimethyl-Phenyl)-Ethyl-1, 3-Dihydro-Imizadol-2-Thion | |
CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
AR018705A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos. | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
GT199900067A (es) | Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica. | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
DE602004016127D1 (de) | Antagonisten der opioidrezeptoren | |
ES2058265T3 (es) | Piperidinas antagonistas de opiaceos. | |
EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
ECSP045077A (es) | Derivados del 3-azabiciclico[3.1.0]hexano como antagonistas del receptor de opioides | |
AR027539A1 (es) | Nuevos derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
MX9204094A (es) | Derivados de fenilalquilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
AR036137A1 (es) | Sales novedosas de derivados anticonvulsivos | |
PA8582201A1 (es) | Indoles 2,7-sustituidos | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
MX9304424A (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
ES2196069T3 (es) | Derivados morfinoides condensados con heterociclos. | |
ES2195089T3 (es) | Benzotiofenos amorfos, procedimientos de preparacion y uso. | |
AR035247A1 (es) | Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
CY1105699T1 (el) | Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας | |
FR2707990B1 (fr) | Nouvelles nitrones utilisables pour le piégeage des radicaux libres. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141203 |